We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
What's in Store for BioSpecifics (BSTC) This Earnings Season?
Read MoreHide Full Article
Shares of BioSpecifics Technologies Corp. have increased 9.7% year to date compared with the industry’s growth of 10.9%.
In the last reported quarter, the company’s earnings beat the Zacks Consensus Estimate. Moreover, BioSpecifics’ earnings beat the Zacks Consensus Estimate in two of the trailing four quarters, while missed in one, with the average positive surprise being 12.46%.
Let’s see how things are shaping up prior to the announcement of the upcoming quarterly results.
Factors Likely to Impact Q1 Results
BioSpecifics develops collagenase-based therapies. The company markets a first-in-class collagenase-based product, Xiaflex, in the United States, which is marketed as Xiapex in Europe.
The company is witnessing continued growth in the two marketed indications for Xiaflex — Peyronie's Disease and Dupuytren's Contracture. We expect this positive trend to reflect in the first-quarter results.
BioSpecifics announced positive data for Xiaflex [collagenase clostridium histolyticum (CCH)] in two new potential indications in the first quarter. The company announced positive top-line results from phase I study of CCH for the treatment of uterine fibroids in October 2018. Also, BioSpecifics’ partner Endo International Plc. announced positive data from the phase III studies of CCH for the treatment of cellulite in November 2018. The company intends to use the phase I data for the development of future clinical studies.
BioSpecifics is taking care of CCH’s development in the uterine fibroids indication and has the right to initiate the development of any new potential indication not licensed by Endo.
Investors’ focus will be on pipeline updates in the first quarter.
What Does the Zacks Model Unveil?
Our proven model does not conclusively show that BioSpecifics will beat on earnings in the to-be-reported quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) to be able to beat estimates. But that is not the case here, as you will see below.
Earnings ESP: BioSpecifics has an Earnings ESP of 0.0%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: The company currently has a Zacks Rank #1, which increases the predictive power of ESP. However, we need to have a positive Earnings ESP to be confident of an earnings beat.
Note that Sell-rated stocks (Zacks Rank #4 or 5) going into an earnings announcement are best avoided.
BioSpecifics Technologies Corp Price and EPS Surprise
Here are some stocks you may want to consider as our model shows that these have the right combination of elements to post an earnings beat this quarter.
Novo Nordisk A/S (NVO - Free Report) has an Earnings ESP of +0.80% and a Zacks Rank #3. The company is scheduled to release first-quarter 2019 results on May 3.
Is Your Investment Advisor Fumbling Your Financial Future?
See how you can more effectively safeguard your retirement with a new Special Report, “4 Warning Signs Your Investment Advisor Might Be Sabotaging Your Financial Future.”
Image: Bigstock
What's in Store for BioSpecifics (BSTC) This Earnings Season?
Shares of BioSpecifics Technologies Corp. have increased 9.7% year to date compared with the industry’s growth of 10.9%.
In the last reported quarter, the company’s earnings beat the Zacks Consensus Estimate. Moreover, BioSpecifics’ earnings beat the Zacks Consensus Estimate in two of the trailing four quarters, while missed in one, with the average positive surprise being 12.46%.
Let’s see how things are shaping up prior to the announcement of the upcoming quarterly results.
Factors Likely to Impact Q1 Results
BioSpecifics develops collagenase-based therapies. The company markets a first-in-class collagenase-based product, Xiaflex, in the United States, which is marketed as Xiapex in Europe.
The company is witnessing continued growth in the two marketed indications for Xiaflex — Peyronie's Disease and Dupuytren's Contracture. We expect this positive trend to reflect in the first-quarter results.
BioSpecifics announced positive data for Xiaflex [collagenase clostridium histolyticum (CCH)] in two new potential indications in the first quarter. The company announced positive top-line results from phase I study of CCH for the treatment of uterine fibroids in October 2018. Also, BioSpecifics’ partner Endo International Plc. announced positive data from the phase III studies of CCH for the treatment of cellulite in November 2018. The company intends to use the phase I data for the development of future clinical studies.
BioSpecifics is taking care of CCH’s development in the uterine fibroids indication and has the right to initiate the development of any new potential indication not licensed by Endo.
Investors’ focus will be on pipeline updates in the first quarter.
What Does the Zacks Model Unveil?
Our proven model does not conclusively show that BioSpecifics will beat on earnings in the to-be-reported quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) to be able to beat estimates. But that is not the case here, as you will see below.
Earnings ESP: BioSpecifics has an Earnings ESP of 0.0%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: The company currently has a Zacks Rank #1, which increases the predictive power of ESP. However, we need to have a positive Earnings ESP to be confident of an earnings beat.
Note that Sell-rated stocks (Zacks Rank #4 or 5) going into an earnings announcement are best avoided.
BioSpecifics Technologies Corp Price and EPS Surprise
BioSpecifics Technologies Corp Price and EPS Surprise | BioSpecifics Technologies Corp Quote
Stocks That Warrant a Look
Here are some stocks you may want to consider as our model shows that these have the right combination of elements to post an earnings beat this quarter.
Glaxo SmithKline plc. (GSK - Free Report) has an Earnings ESP of +3.55% and a Zacks Rank #3. The company is scheduled to release first-quarter 2019 results on May 1. You can see the complete list of today’s Zacks #1 Rank stocks here.
Novo Nordisk A/S (NVO - Free Report) has an Earnings ESP of +0.80% and a Zacks Rank #3. The company is scheduled to release first-quarter 2019 results on May 3.
Is Your Investment Advisor Fumbling Your Financial Future?
See how you can more effectively safeguard your retirement with a new Special Report, “4 Warning Signs Your Investment Advisor Might Be Sabotaging Your Financial Future.”
Click to get it free >>